Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.34 |
| ▸ | EP300 | Q09472 | 4/20 | 0.33 |
| ▸ | CTSL | P07711 | 8/20 | 0.32 |
| ▸ | CTSB | P07858 | 4/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | CCNK | O75909 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21112135 | 0.93 | CTSS (0.36) | CTSSEP300CTSLCTSBCCNK | |
| SCHEMBL29640364 | 0.89 | ELANE (0.31) | ELANEMGLLROCK2 | |
| SCHEMBL28402063 | 0.87 | ELANE (0.33) | CTSSEP300ELANEMGLLROCK2 | |
| SCHEMBL21148892 | 0.87 | ELANE (0.33) | CTSSEP300ELANEMGLLROCK2 | |
| SCHEMBL21112313 | 0.82 | MGLL (0.32) | EP300ELANEMGLLROCK2 | |
| SCHEMBL20900263 | 0.81 | MGLL (0.35) | CTSSEP300CTSLCTSBELANE | |
| SCHEMBL20900266 | 0.81 | MGLL (0.35) | CTSSEP300CTSLCTSBELANE | |
| SCHEMBL23114939 | 0.79 | MEN1 (0.37) | CTSSEP300ELANEMGLLROCK2 | |
| SCHEMBL21149554 | 0.79 | MEN1 (0.37) | CTSSEP300ELANEMGLLROCK2 | |
| SCHEMBL29640161 | 0.79 | EP300 (0.35) | CTSSEP300CTSLCTSBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-111212832-A | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as HIV protease inhibitors | 吉利德科学公司 | 2020-05-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | CTSS 27/4885EP300 880/4885CTSL 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.